KYOWA KIRIN CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.85 USD | +0.27% |
|
0.00% | +22.18% |
| 07-03 | Kyowa Kirin Buys Back Shares | MT |
| 07-02 | Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. | CI |
| Sales 2024 * | 477B 3.01B 4.11B | Sales 2025 * | 490B 3.09B 4.23B | Capitalization | 1,639B 10.33B 14.14B |
|---|---|---|---|---|---|
| Net income 2024 * | 65.32B 412M 563M | Net income 2025 * | 69.12B 436M 596M | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | 328B 2.07B 2.83B | Net cash position 2025 * | 361B 2.28B 3.12B | EV / Sales 2025 * | 2.61 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
23.7
x | Employees | 5,974 |
| Yield 2024 * |
1.86% | Yield 2025 * |
1.92% | Free-Float | 45.41% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.27% | ||
| Current month | +0.27% | ||
| 6 months | +0.88% | ||
| Current year | +22.18% |
Current year
19.35
19.85
1 year
15.6019.85
3 years
15.6019.85
5 years
15.6019.85
10 years
15.6019.85
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 86-03-31 | |
Masashi Miyamoto
PSD | President | 65 | 85-03-31 |
| Chief Tech/Sci/R&D Officer | 62 | 10-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 21-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 69 | 22-02-28 |
| Director/Board Member | 67 | 08-09-30 |
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
3,107
JPY
Average target price
3,095
JPY
Spread / Average Target
-0.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.73% | 72.01B | |
| +41.28% | 5.26B | |
| -18.53% | 4.64B | |
| +18.24% | 3.7B | |
| +27.58% | 2.3B | |
| -39.52% | 1.8B | |
| -45.87% | 1.7B | |
| -0.50% | 1.64B | |
| -0.62% | 1.58B |
- Stock Market
- Equities
- 4151 Stock
- KYKOY Stock
